ALT - Altimmune, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
2.0800
-0.0500 (-2.35%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.1300
Open2.0900
Bid0.0000 x 800
Ask0.0000 x 900
Day's Range2.0600 - 2.1400
52 Week Range1.7000 - 36.2500
Volume72,565
Avg. Volume282,574
Market Cap31.903M
Beta (3Y Monthly)2.18
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2017-01-20
1y Target EstN/A
Trade prices are not sourced from all markets
  • Germantown biopharma regains compliance with Nasdaq
    American City Business Journals

    Germantown biopharma regains compliance with Nasdaq

    The Nasdaq Hearings Panel concluded Neuralstem showed compliance by meeting the minimum $1 bid price requirement.

  • Not just a vaccine company: How this Gaithersburg biotech CEO plans to grow the business
    American City Business Journals

    Not just a vaccine company: How this Gaithersburg biotech CEO plans to grow the business

    The Gaitherburg biotech’s CEO, not yet a year into his tenure, sees the prospect of more acquisitions or licensing deals going forward.

  • Altimmune to acquire California company for up to $93M
    American City Business Journals

    Altimmune to acquire California company for up to $93M

    The deal puts Spitfire’s flagship product candidate — a treatment for nonalcoholic steatohepatitis, or NASH — into Altimmune’s pipeline of flu and anthrax vaccines.

  • Germantown stem cell therapy company proposes $7M offering amid delisting threat
    American City Business Journals

    Germantown stem cell therapy company proposes $7M offering amid delisting threat

    The company’s future on the Nasdaq hangs in the balance, as its share price continues to sit below a buck in the wake of a delisting threat from the exchange.

  • Benzinga

    Altimmune To Acquire Spitfire Pharma For $5M, Add NASH Drug To Portfolio

    Altimmune (NASDAQ: ALT ) shares are trading higher after the company announced it will acquire Spitfire Pharma , which will add a non-alcoholic steatohepatitis (NASH) drug candidate to the company's portfolio. ...

  • MarketWatch

    Altimmune's stock soars after adding NASH candidate with purchase of Spitfire Pharma

    Shares of Altimmune Inc. soared 14% in premarket trading Tuesday, after the biopharmaceutical company announced a deal to buy Spitfire Pharma Inc., which is developing a treatment for non-alcoholic steatohepatitis, known as NASH. Altimmune will make an upfront payment of $5 million to Spitfire shareholders, who will also be eligible to receive an additional $8 million in regulatory and clinical milestones and up to $80 million in sales-based milestones. The deal is expected to close in July. Spitfire's NASH product candidate SP-1373 will be renamed ALT-801. "Compelling preclinical data generated by Spitfire suggests that ALT-801 could reverse obesity, a primary cause of NASH, thereby reducing excess liver fat, inflammation and fibrosis associated with the disease," said Altimmune Chief Executive Vipin Garg. Altimmune's stock has tumbled 21.1% over the past three months through Monday, while the iShares Nasdaq Biotechnology ETF has lost 4.3% and the S&P 500 has gained 3.4%.

  • Altimmune News: ALT Stock Skyrockets on Positive Flu Vaccine Data
    InvestorPlace

    Altimmune News: ALT Stock Skyrockets on Positive Flu Vaccine Data

    Altimmune news concerning the results from a Phase 2 extension study of the company's NasoVAX has ALT stock heading higher today.Source: Shutterstock Altimmune (NASDAQ:ALT) says that it saw strong results from an extension to the study that has it checking in on patients one year after its completion. This includes 100% of patients that returned for the study extension still being seroprotected.The Altimmune news about its intranasal influenza vaccine candidate NasoVAX notes that patients in the extension were also saw a seroconversion rate that was unchanged from last year. It is also worth noting that these patients were from the highest dosage level of the study.InvestorPlace - Stock Market News, Stock Advice & Trading Tips"We are excited about the continued positive NasoVAX results and believe that if approved, NasoVAX has the potential to capture a significant portion of the global flu vaccine market," Vipin Garg, Ph.D., President and CEO of Altimmune, said in a statement. "Based on the continued positive data, we are seeking development and commercialization partnerships for our NasoVAX program. This will allow us to focus on our strategy of building a pipeline of multiple early to mid-stage assets." * Top 7 Service Sector Stocks That Will Pay You to Own Them The original study from Altimmune about using NasoVAX as an influenza vaccine had 13 people receiving the highest dosage of the vaccine. All 13 were invited to return for the extension, but only eight chose to do so.ALT stock was up 15% as of noon Tuesday and is up 11% since the start of the year. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Financial Stocks to Invest In Today * 7 Single-Digit P/E Stocks With Massive Upside * 5 Chip Stocks on the Rise As of this writing, William White did not hold a position in any of the aforementioned securities.Compare Brokers The post Altimmune News: ALT Stock Skyrockets on Positive Flu Vaccine Data appeared first on InvestorPlace.

  • Gaithersburg biotech CEO to step down
    American City Business Journals

    Gaithersburg biotech CEO to step down

    The chief executive will stay in his role, and on the board, until his successor is appointed or early next year, whichever comes first.

  • Why Altimmune Stock Is Sliding Lower Today
    InvestorPlace

    Why Altimmune Stock Is Sliding Lower Today

    According to Altimmune (NASDAQ:ALT), the company has entered into a purchase agreement with a several institutional investors. The common units include one common share of Altimmune stock, as well as a warrant to purchase an additional share for the same price. It also includes a warrant to purchase an additional share of ALT stock for a price of $5.39.

  • Why Altimmune Stock Is Skyrocketing Today
    InvestorPlace

    Why Altimmune Stock Is Skyrocketing Today

    About two weeks ago, the Gaithersburg, Maryland-based company said that its intranasal egg-free flu vaccine medication NasoVax yielded positive data from its Phase 2a study. Altimmune’s vaccine candidate also proved to elicit a considerable T cell immune response when compared to Fluzone, which is a licensed injected influenza vaccine. Altimmune also has an anthrax vaccine, as well as a cancer immunotherapeutic product in Oncosyn that it is developing at the moment.